Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741636663> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2741636663 abstract "Background and aim: Anti-angiogenesis is a promising treatment in endometrioid endometrial cancer (EEC) while the present anti-angiogenic drugs still have limitations such as drug tolerance, toxicity profile and substantial costs. (-)-Epigallocatechin-3-gallate (EGCG), the major polyphenol of green tea, is associated with anti-cancer benefits, but it is unstable and has poor bioavailability. These limitations can be solved through peracetate ester of EGCG as a prodrug (ProEGCG), while little is known about its anti-angiogenesis effect in cancer. The objective is to study the effect and underling mechanism of ProEGCG on EEC angiogenesis. Methods and Results: Tumor xenografts were established by subcutaneous injection of a human EEC cell line (RL95-2) into nude mice, and ProEGCG or control was orally administered every day. 35 days later, mice treated with ProEGCG showed significant reduction in lesion size and MVD without major toxic effects compared to control. To find out how ProEGCG inhibits tumor progress and angiogenesis, microarray analysis of excised lesions was conducted and indicated that HIF-1α, VEGFA and CXCR4 were downregulated by ProEGCG. Compared to control, immunohistochemistry showed that ProEGCG reduced expression of HIF-1α and VEGFA in RL95-2 cells and decreased CXCR4 expression in tumor-associated macrophages (TAMs) and endothelial cells (ECs). To further study the role of ProEGCG on EEC cells, qRT-PCR and Western blotting proved that hypoxia (1% O2) upregulated the level of HIF-1α and VEGFA in EEC cell lines, which was reversed by ProEGCG through inhibiting hypoxia-induced ROS formation. It is known that TAMs play an important role in tumor angiogenesis, and double immunofluorescence of F4/80 and CD206 antibodies in xenografts was applied and found that TAMs infiltration was reduced in ProEGCG group with decreased VEGFA in TAMs. Moreover, proliferation and migration of ECs are critical for tumor angiogenesis. To study the effect of ProEGCG on ECs, tube formation and invasion assays were conducted. The addition of ProEGCG on ECs showed less capillary tube-like structure formation and less invaded ECs by inhibition of CXCR4 expression on ECs. However, it was still unclear if CXCL12, the ligand of CXCR4, was affected. Immunostaining for CXCL12 in tumor lesions indicated that ProEGCG decreased CXCL12 expression in cancer and stromal cells, which was further confirmed in primary human endometrial stromal cells by addition of ProEGCG. Conclusion: Our study was the first to reveal the mechanism of anti-angiogenesis of ProEGCG, which decreased HIF1α/VEGFA expression in tumor cells, inhibited recruitment and differentiation of TAMs and tube formation of endothelial cells via CXCL12/CXCR4 reduction. These findings provided that ProEGCG would be an effective, safe and economic anti-angiogenic drug for EEC. Citation Format: Jianzhang Wang, Chi Wai Man, Xueying Yang, Joseph Kwong, Q. Ping Dou, Tak Hang Chan, Chi Chiu Wang. A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate served as a potentially novel angiogenesis inhibitor in endometrioid endometrial cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 162. doi:10.1158/1538-7445.AM2017-162" @default.
- W2741636663 created "2017-08-08" @default.
- W2741636663 creator A5009893983 @default.
- W2741636663 creator A5022033472 @default.
- W2741636663 creator A5024674202 @default.
- W2741636663 creator A5031515836 @default.
- W2741636663 creator A5051071198 @default.
- W2741636663 creator A5083833865 @default.
- W2741636663 creator A5090702709 @default.
- W2741636663 date "2017-07-01" @default.
- W2741636663 modified "2023-09-27" @default.
- W2741636663 title "Abstract 162: A prodrug of green tea polyphenol (-)-epigallocatechin-3-gallate served as a potentially novel angiogenesis inhibitor in endometrioid endometrial cancer" @default.
- W2741636663 doi "https://doi.org/10.1158/1538-7445.am2017-162" @default.
- W2741636663 hasPublicationYear "2017" @default.
- W2741636663 type Work @default.
- W2741636663 sameAs 2741636663 @default.
- W2741636663 citedByCount "0" @default.
- W2741636663 crossrefType "proceedings-article" @default.
- W2741636663 hasAuthorship W2741636663A5009893983 @default.
- W2741636663 hasAuthorship W2741636663A5022033472 @default.
- W2741636663 hasAuthorship W2741636663A5024674202 @default.
- W2741636663 hasAuthorship W2741636663A5031515836 @default.
- W2741636663 hasAuthorship W2741636663A5051071198 @default.
- W2741636663 hasAuthorship W2741636663A5083833865 @default.
- W2741636663 hasAuthorship W2741636663A5090702709 @default.
- W2741636663 hasConcept C108215921 @default.
- W2741636663 hasConcept C121608353 @default.
- W2741636663 hasConcept C126322002 @default.
- W2741636663 hasConcept C146285616 @default.
- W2741636663 hasConcept C167734588 @default.
- W2741636663 hasConcept C185592680 @default.
- W2741636663 hasConcept C2776056115 @default.
- W2741636663 hasConcept C2777025900 @default.
- W2741636663 hasConcept C2777192995 @default.
- W2741636663 hasConcept C2778004101 @default.
- W2741636663 hasConcept C2780394083 @default.
- W2741636663 hasConcept C502942594 @default.
- W2741636663 hasConcept C55493867 @default.
- W2741636663 hasConcept C70899900 @default.
- W2741636663 hasConcept C71924100 @default.
- W2741636663 hasConcept C98274493 @default.
- W2741636663 hasConceptScore W2741636663C108215921 @default.
- W2741636663 hasConceptScore W2741636663C121608353 @default.
- W2741636663 hasConceptScore W2741636663C126322002 @default.
- W2741636663 hasConceptScore W2741636663C146285616 @default.
- W2741636663 hasConceptScore W2741636663C167734588 @default.
- W2741636663 hasConceptScore W2741636663C185592680 @default.
- W2741636663 hasConceptScore W2741636663C2776056115 @default.
- W2741636663 hasConceptScore W2741636663C2777025900 @default.
- W2741636663 hasConceptScore W2741636663C2777192995 @default.
- W2741636663 hasConceptScore W2741636663C2778004101 @default.
- W2741636663 hasConceptScore W2741636663C2780394083 @default.
- W2741636663 hasConceptScore W2741636663C502942594 @default.
- W2741636663 hasConceptScore W2741636663C55493867 @default.
- W2741636663 hasConceptScore W2741636663C70899900 @default.
- W2741636663 hasConceptScore W2741636663C71924100 @default.
- W2741636663 hasConceptScore W2741636663C98274493 @default.
- W2741636663 hasLocation W27416366631 @default.
- W2741636663 hasOpenAccess W2741636663 @default.
- W2741636663 hasPrimaryLocation W27416366631 @default.
- W2741636663 hasRelatedWork W1642383193 @default.
- W2741636663 hasRelatedWork W1771551064 @default.
- W2741636663 hasRelatedWork W1988975320 @default.
- W2741636663 hasRelatedWork W1992092426 @default.
- W2741636663 hasRelatedWork W1999797961 @default.
- W2741636663 hasRelatedWork W2002532999 @default.
- W2741636663 hasRelatedWork W2009545908 @default.
- W2741636663 hasRelatedWork W2059116916 @default.
- W2741636663 hasRelatedWork W2110075349 @default.
- W2741636663 hasRelatedWork W2119048971 @default.
- W2741636663 hasRelatedWork W2178879278 @default.
- W2741636663 hasRelatedWork W2413054635 @default.
- W2741636663 hasRelatedWork W2511428588 @default.
- W2741636663 hasRelatedWork W2536593260 @default.
- W2741636663 hasRelatedWork W2761665465 @default.
- W2741636663 hasRelatedWork W2800826373 @default.
- W2741636663 hasRelatedWork W2809968076 @default.
- W2741636663 hasRelatedWork W3031257405 @default.
- W2741636663 hasRelatedWork W3044426045 @default.
- W2741636663 hasRelatedWork W2339615285 @default.
- W2741636663 isParatext "false" @default.
- W2741636663 isRetracted "false" @default.
- W2741636663 magId "2741636663" @default.
- W2741636663 workType "article" @default.